comprehensive mass spectrometry based biomarker discovery and validation platform as applied to diabetic kidney disease
Clicks: 161
ID: 196323
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
4.5
/100
15 views
15 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
A protein biomarker discovery workflow was applied to plasma samples from patients at different stages of diabetic kidney disease. The proteomics platform produced a panel of significant plasma biomarkers that were statistically scrutinised against the current gold standard tests on an analysis of 572 patients. Five proteins were significantly associated with diabetic kidney disease defined by albuminuria, renal impairment (eGFR) and chronic kidney disease staging (CKD Stage ≥1, ROC curve of 0.77). The results prove the suitability and efficacy of the process used, and introduce a biomarker panel with the potential to improve diagnosis of diabetic kidney disease.
| Reference Key |
bringans2017eupacomprehensive
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Scott D. Bringans;Jun Ito;Thomas Stoll;Kaye Winfield;Michael Phillips;Kirsten Peters;Wendy A. Davis;Timothy M.E. Davis;Richard J. Lipscombe |
| Journal | technological and economic development of economy |
| Year | 2017 |
| DOI |
10.1016/j.euprot.2016.12.001
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.